Real-world treatment patterns and outcomes with olutasidenib after venetoclax in <i>IDH1</i> -mutated AML using EHR data.
Yasmin Abaza(Northwestern University), Catherine Lai(University of Pennsylvania), Timothy Werwath, Pinkal Desai(NewYork–Presbyterian Hospital), Amber Thomassen(Rigel (United States)), Aaron D. Sheppard(Rigel (United States)), Jorge E. Cortes(Augusta University Health)
Cited by 0
Related Papers
Somatic mutations precede acute myeloid leukemia years before diagnosis
|Nature Medicine|2018|621
Association of Clonal Hematopoiesis With Incident Heart Failure
|Journal of the American College of Cardiology|2021|220
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
|Blood Advances|2020|191
Clonal hematopoiesis associated with epigenetic aging and clinical outcomes
|Aging Cell|2021|134
Statin use and all-cancer survival: prospective results from the Women’s Health Initiative
|British Journal of Cancer|2016|99